Obagi Skin Care Products Face Treatments

Obagi in the News

Published Clinical Study Reports

Obagi SYstem Significantly Improves Photodamaged Skin Better... Study in peer-reviewed COSMETIC DERMATOLOGY Confirms Improved Treatment for Individuals Suffering From Premature Skin Damage.

May 01, 2006

Study in peer-reviewed COSMETIC DERMATOLOGY Confirms Improved Treatment for Individuals Suffering From Premature Skin Damage.

LONG BEACH, CA, May 2, 2006 – Obagi Medical Products, Inc. (Obagi), today announced the positive clinical results for the Obagi® Nu-Derm® System to treat photodamaged skin were published in the April 2006 edition of the peer-reviewed journal of Cosmetic Dermatology.

In the 387-person randomized study, patients received one of four treatment strategies over a 24-week period: the Obagi Nu-Derm System, a regimen of systematically dosed over-the-counter (OTC) products with hydroquinone plus tretinoin; hydroquinone plus OTC products; tretinoin plus OTC products, and OTC products alone. After 12 and 24 weeks of treatment, improvements using the Obagi Nu-Derm System were greater than and statistically superior to those observed with the other treatment regimens. At 12 weeks, the Obagi Nu-Derm System patients experienced a two-fold improvement in fine lines and wrinkles than those observed in all other groups. At 24 weeks, Obagi Nu-Derm patients experienced a four-fold improvement in perioral and periocular wrinkles, as well as markedly greater improvements in fine lines and laxity compared to other groups. No adverse events were reported in the Obagi Nu-Derm System group.

“The use of the Obagi Nu-Derm System in the treatment of photodamaged skin provides significantly greater improvements in wrinkles, laxity, and mottled hyperpigmentation than other systems tested,” said Dr. James H. Herndon, Jr., lead investigator in the study.

Steve Carlson, Obagi's President and CEO, stated “We are pleased to see the final results of this important study published in Cosmetic Dermatology. Obagi hopes to corroborate and extend these results with other studies already underway that demonstrate the positive and synergistic effects of combining the Obagi Nu-Derm System with other cosmetic procedures.”

The study, titled “Efficacy of a Tretinoin/Hydroquinone-Based Skin Health System in the Treatment of Facial Photodamage” was published in the April 2006 issue of Cosmetic Dermatology (Volume 19 No. 4: Pages 255-261) by James H. Herndon, Jr., M.D., Thomas J. Stephens, Ph.D., and Moyna L. Sigler, Ph.D. Obagi provided products and financial support for the study.

About Obagi Medical Products, Inc.
Obagi, a leader in the physician-dispensed skin care channel, is a specialty pharmaceutical company focused on the aesthetic and skin health markets. Obagi develops and commercializes prescription-based, topical skin health systems that enable physicians to treat a range of skin conditions, including pre-mature aging, photo-damage, hyperpigmentation, acne and soft tissue deficits, such as fine lines and wrinkles. Obagi launched its first skincare system, Obagi Nu-Derm, in 1988; In Japan, Obagi products are currently available in non-prescription strengths over the counter in drug stores and in medical strength systems through physicians.